ProQR Therapeutics reported Q1 2026 financial results with €81.1 million cash supporting runway into mid-2027 and pipeline progress including AX-0810 target engagement data on track for Q2 2026.
Key takeaways
Cash and equivalents €81.1 million at March 31, 2026, down from €92.4 million at year-end 2025, runway into mid-2027.
Net loss €13.4 million or €0.13 per diluted share vs €10.1 million or €0.10 last year.
AX-0810 Phase 1 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected for Phase 2 via China IIT with data H1 2027.
Pipeline advances: AX-0811 CTA mid-2026, data YE 2026; AX-0422 CTA early 2027, data H1 2027; AX-2911 FIH H1 2027.
Strategic partnership with Ginkgo Bioworks and new AI Advisory Board to enhance Axiomer platform.
Dr. Lykke Hinsch Gylvin nominated for Board, pending approval at June 2, 2026 AGM.